BDTX_OUT_1 [2025-03-19 10:25:48 -0400] 2146 Bytes | 572 tokens | Cum: 572 tkns (7.15% of 8k)
==========================================================================

We need a winner today and it's already 10:25:46 AM on Wednesday March 19, 2025 ET (UTC-0400) ... So let's find out if Black Diamond Therapeutics (BDTX) is going up or if it's going nowhere fast. So, I pulled together a bunch of data for you to look over real fast. It's at 2.2411 up from 1.68. Is there something here we can get excited about? Help me analyze.

Here's the first list of news for Black Diamond Therapeutics:

C1 - Today 07:00AM - Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
C2 - Mar-06-25 04:09PM - Black Diamond: Q4 Earnings Snapshot
C3 - Mar-06-25 04:09PM 04:01PM - Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
C4 - Feb-19-25 09:15AM - NAYA Biosciences Announces Nomination of New Board Members
C5 - Jan-12-25 06:05AM - Raymond James Predicts Up to ~930% Rally for These 2 Strong Buy Stocks
C6 - Nov-05-24 09:00AM - Black Diamond: Q3 Earnings Snapshot
C7 - Nov-05-24 09:00AM 08:00AM - Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
C8 - Nov-01-24 08:00AM - Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

ONLY 3 RULES for AI:
==============
1) This is a document retrieval system. You are the analyst-investigator.
2) You can request items from any list to get more details about Black Diamond Therapeutics (BDTX)
3) AFTER requesting and reading News and SEC filings you'll get tokens to write a summary, set a score and high price target, and finally take an exit quiz.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.

Thank you for your analysis of Black Diamond Therapeutics.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!

Please request a document, read, summarize and score. Say something like "C1".

BDTX_OUT_3 [2025-03-19 10:25:52 -0400] 967 Bytes | 271 tokens | Cum: 845 tkns (10.56% of 8k)
==========================================================================

Showing C1 (chunk 1 of 9): C1:
**Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy**
Date: Today 07:00AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/19/3045227/0/en/Servier-and-Black-Diamond-Therapeutics-Announce-Global-Licensing-Agreement-for-BDTX-4933-A-Targeted-Oncology-Therapy.html

March 19, 2025 07:00 ET| Source:Black Diamond Therapeutics, IncBlack Diamond Therapeutics, Inc

SURESNES, France and CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group governed by a non-profit foundation, and Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced a strategic worldwide licensing agreement for BDTX-4933, a potential be

-- More? (MOR) or Next section? (NEX)

BDTX_OUT_5 [2025-03-19 10:25:54 -0400] 851 Bytes | 255 tokens | Cum: 1106 tkns (13.83% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-19T12:40:07Z - Daily Game Plan - Opening Print...
A2 - 2025-03-19T12:12:15Z - Black Diamond Therapeutics (NASDAQ:BDTX) Price Target Raised to $12.00...
A3 - 2025-03-19T12:44:09Z - Pre-market Movers: Leishen Energy, Black Diamond Therapeutics, FST Corp., 5E Advanced Materials, CAR...
A4 - 2025-03-19T12:27:02Z - Futures Rise With All Eyes On Fed...
A5 - 2025-03-19T11:53:15Z - Servier pays $70M to polish Black Diamond's deprioritized solid tumor prospect...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

BDTX_OUT_7 [2025-03-19 10:25:55 -0400] 967 Bytes | 224 tokens | Cum: 1332 tkns (16.65% of 8k)
==========================================================================

Showing A1 (chunk 1 of 8): A1:
**Daily Game Plan - Opening Print**Date: 2025-03-19Source: {'uri': 'mrtopstep.com', 'dataType': 'news', 'title': 'Mr TopStep'}URL: https://mrtopstep.com/daily-game-plan-387/World stocks fluctuated ahead of the Federal Reserve interest-rate decision and new dot plot. Sentiment was hit after Russia's Putin declined Donald Trump's bid for

a 30-day ceasefire in Ukraine, agreeing instead to limit attacks on the country's energy infrastructure. Russia and Ukraine accused each other of launching drone attacks that struck civilian targets including infrastructure, just hours after Putin told President

Trump he would pause attacks on Ukraine's energy system. Zelenskiy stated that Ukraine will never recognize territories occupied by Moscow as Russian and that the size of his army shouldn't be a subject for talks with Putin. The Bank of Japan kept its benchmark

rate unchanged and cited worri

-- More? (MOR) or Next section? (NEX)

BDTX_OUT_9 [2025-03-19 10:25:57 -0400] 1220 Bytes | 353 tokens | Cum: 1687 tkns (21.09% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-03-19T11:00:00Z - Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
B2 - 2025-01-29T18:00:00Z - BRAF Inhibitors Market to Register Incremental Growth During the Study Period (2020–2034) | DelveInsight
B3 - 2024-11-05T13:00:00Z - Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
B4 - 2024-10-07T20:01:00Z - Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway
B5 - 2024-09-22T14:00:00Z - Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
B6 - 2024-09-14T07:30:00Z - Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

BDTX_OUT_11 [2025-03-19 10:26:05 -0400] 744 Bytes | 191 tokens | Cum: 1880 tkns (23.50% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/03/19/3045227/0/en/Servier-and-Black-Diamond-Therapeutics-Announce-Global-Licensing-Agreement-for-BDTX-4933-A-Targeted-Oncology-Therapy.htmlServier and Black Diamond Therapeutics have announced a global licensing agreement for BDTX-4933, a targeted oncology therapy in Phase 1 development. Servier will lead the development and commercialization of the therapy, with Black Diamond receiving an upfront payment and potential milestone and royalty payments.

-- More? (MOR) or Next section? (NEX)

BDTX_OUT_13 [2025-03-19 10:26:07 -0400] 1115 Bytes | 288 tokens | Cum: 2289 tkns (28.61% of 8k)
==========================================================================

This is our list of SEC filings.
Read it just by asking.
Don't miss breaking filings!

S1 - 2025-03-19 8-K Item 1.01. Entry into a Material Definitive Agrmt.

On March 18, 2025, Black Diamond Therapeutics, Inc. (the Company) entered into a License Agrmt (the License Agrmt) with Servier Pharmaceuticals LLC (Servier). Under the terms of the License Agrmt, the Company gr...

S2 - 2025-03-06 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

The following discussion and analysis should be read in conjunction with our audited CONS financial statements and related notes included elsewhere in this Annual Report. This ...

S3 - 2025-03-06 8-K Item 2.02. Results of Oper and Fin Cond.

On March 6, 2025, Black Diamond Therapeutics, Inc. announced its financial results for the year and three months ended December 31, 2024. The full text of the press release issued in connection with the announcement is f...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing - but what fun is that?
Response limited to 3 chars.

BDTX_OUT_15 [2025-03-19 10:26:08 -0400] 967 Bytes | 178 tokens | Cum: 2469 tkns (30.86% of 8k)
==========================================================================

Showing S2 (chunk 1 of 6): S2:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis should be read in conjunction with our audited consolidated financial statements and related notes included elsewhere in this Annual Report. This discussion and analysis and other parts of this Annual Report contain forward-looking statements based upon current beliefs, plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under Part I, Item 1A Risk Factors and elsewhere in this Annual Report. You should carefully read the Risk Factors section of this

-- More? (MOR) or Next section? (NEX)

BDTX_OUT_17 [2025-03-19 10:26:27 -0400] 6447 Bytes | 1672 tokens | Cum: 4143 tkns (51.79% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+--------------------+-----------------------+-------------------------+----------------------+----------------------+
| Prev Close: 1.68 | RSI (14): 58.48 | Perf Quarter: -13.11% | Insider Trans: 0.00% | Sales Q/Q: - | ROE: -69.67% |
+---------------------+--------------------+-----------------------+-------------------------+----------------------+----------------------+
| Target Price: 13.67 | ATR (14): 0.22 | Index: RUT | Option/Short: Yes / Yes | Sales past 5Y: 0.00% | ROI: -68.26% |
+---------------------+--------------------+-----------------------+-------------------------+----------------------+----------------------+
| Price: 2.22 | SMA20: 16.54% | Market Cap: 126.04M | Short Float: 17.17% | Income: -69.68M | Sales Surprise: - |
+---------------------+--------------------+-----------------------+-------------------------+----------------------+----------------------+
| Change: 32.41% | SMA50: 2.50% | Shs Outstand: 56.64M | Short Ratio: 9.64 | Employees: 24 | EPS Surprise: 11.03% |
+---------------------+--------------------+-----------------------+-------------------------+----------------------+----------------------+
| Volume: 75,528,994 | SMA200: -40.45% | Shs Float: 43.16M | Short Interest: 7.41M | Debt/Eq: 0.27 | P/E: - |
+---------------------+--------------------+-----------------------+-------------------------+----------------------+----------------------+
| Avg Volume: 768.64K | Perf Week: 24.27% | Inst Own: 75.06% | Beta: 2.79 | Sales Y/Y TTM: - | Earnings: Mar 06 AMC |
+---------------------+--------------------+-----------------------+-------------------------+----------------------+----------------------+
| Rel Volume: 666.48 | Perf Month: -2.43% | Insider Own: 23.83% | Sales: 0.00M | Profit Margin: - | |
+---------------------+--------------------+-----------------------+-------------------------+----------------------+----------------------+

The next section covers any insider trading.
If this section is blank, it's because there've been no recent filings.

Inside Trans: Black Diamond Therapeutics, Inc. (BDTX) by Hatzis-Schoch Brent (SEE REMARKS) on 2025-01-30
- Common Stock: 75000 shares at $0 (D) Footnote: Represents a grant of Restricted Stock Units ("RSUs") under the Black Diamond Therapeutics, Inc. 2020 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: 50% of the RSUs shall vest on January 30, 2026 and the remaining 50% of the RSUs shall vest on January 30, 2027, subject to the Reporting Person's continued service on each such vesting date.
- Stock Option (Right to Buy): 175000 shares at $0 (D)

Inside Trans: Black Diamond Therapeutics, Inc. (BDTX) by Jones Erika (SEE REMARKS) on 2025-01-30
- Common Stock: 75000 shares at $0 (D) Footnote: Represents a grant of Restricted Stock Units ("RSUs") under the Black Diamond Therapeutics, Inc. 2020 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: 50% of the RSUs shall vest on January 30, 2026 and the remaining 50% of the RSUs shall vest on January 30, 2027, subject to the Reporting Person's continued service on each such vesting date.
- Stock Option (Right to Buy): 125000 shares at $0 (D)

Inside Trans: Black Diamond Therapeutics, Inc. (BDTX) by Buck Elizabeth (CHIEF SCIENTIFIC OFFICER) on 2025-01-30
- Common Stock: 75000 shares at $0 (D) Footnote: Represents a grant of Restricted Stock Units ("RSUs") under the Black Diamond Therapeutics, Inc. 2020 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: 50% of the RSUs shall vest on January 30, 2026 and the remaining 50% of the RSUs shall vest on January 30, 2027, subject to the Reporting Person's continued service on each such vesting date.
- Stock Option (Right to Buy): 175000 shares at $0 (D)

Inside Trans: Black Diamond Therapeutics, Inc. (BDTX) by Yurasov Sergey (CHIEF MEDICAL OFFICER) on 2025-01-30
- Common Stock: 75000 shares at $0 (D) Footnote: Represents a grant of Restricted Stock Units ("RSUs") under the Black Diamond Therapeutics, Inc. 2020 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: 50% of the RSUs shall vest on January 30, 2026 and the remaining 50% of the RSUs shall vest on January 30, 2027, subject to the Reporting Person's continued service on each such vesting date.
- Stock Option (Right to Buy): 200000 shares at $0 (D)

Inside Trans: Black Diamond Therapeutics, Inc. (BDTX) by Velleca Mark A. (PRESIDENT & CEO) on 2025-01-30
- Common Stock: 75000 shares at $0 (D) Footnote: Represents a grant of Restricted Stock Units ("RSUs") under the Black Diamond Therapeutics, Inc. 2020 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: 50% of the RSUs shall vest on January 30, 2026 and the remaining 50% of the RSUs shall vest on January 30, 2027, subject to the Reporting Person's continued service on each such vesting date.
- Stock Option (Right to Buy): 500000 shares at $0 (D)

Now we've reached the end of the analysis.
You are now allotted tokens to make a final analysis summary.
Please don't use tokens to explain why you didn't have enough information.
Save that for the survey that comes last.

Finish the summary with two scores: MARKET_SCORE[] and PRICE_TARGET[]

If you think there's a 90% likelihood of an upward moves, say: MARKET_SCORE[90]
If you think the high today will be 50% higher, add to the price. Eg., If the price is $5.00, add 50%: PRICE_TARGET[$7.50]
PRICE_TARGET is the highest it is expected to rise today, so it cannot be less than the current price.

After you have completed that, please provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-10 words headline for news story from first summary paragraph]